Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Evaluate the Safety, Efficacy, and Protection of Micardis 80 mg/Micardis Plus 80/12.5 mg From Cardiovascular Risks in a 24 Weeks Observational Study in Patients With Essential Hypertension Who Have at Least One Other Known Cardio-vascular Risk Factor

NCT00936208 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00936208
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00936208 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Evaluate the Safety, Efficacy, and Protection of Micardis 80 mg/Micardis Plus 80/12.5 mg From Cardiovascular Risks in a 24 Weeks Observational Study in Patients With Essential Hypertension Who Have at Least One Other Known Cardio-vascular Risk Factor
Lead sponsor
Boehringer Ingelheim
Phase
Observational
Overall status
Completed
Start date
May 31, 2009
Completion date
Not reported
Enrollment
3,184 (actual)
Sites
120

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension